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Abstract— Thyroid cancer is the commonest endocrine 
malignancy. Mutation in the BRAF serine/threonine kinase is the 
most frequent genetic alteration in thyroid cancer.  Target therapy 
for advanced and poorly differentiated thyroid carcinomas include 
BRAF pathway inhibitors. Here, we evaluated the role of MAP3K8 
expression as a potential driver of resistance to BRAF inhibition in 
thyroid cancer. By analyzing Gene Expression Omnibus data 
repository, across all thyroid cancer histotypes, we found that 
MAP3K8 is up-regulated in poorly differentiated thyroid carcinomas 
and its expression is related to a stem cell like phenotype and a poorer 
prognosis and survival. Taken together these data unravel a novel 
mechanism for thyroid cancer progression and chemo-resistance 
and confirm previous results obtained in cultured thyroid cancer 
stem cells  
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I.  INTRODUCTION  
Thyroid cancer is the most common type of endocrine tumor 
showing an increasing incidence over the last three decades. 
Malignant carcinoma of the thyroid arises from two different cell 
types, follicular and parafollicular. Follicular cells are involved 
in the production of thyroid hormones and they may give rise to 
well-differentiated and anaplastic thyroid carcinomas. The 
parafollicular C cells are responsible for the calcitonin 
production and they may give rise to medullary thyroid cancer 
(MTC) [1]. 
BRAF participates in the production of a protein involved in 
the transmission of chemical signals from outside the cell to the 
nucleus. This protein is part of the RAS/MAPK signaling 
pathway, which controls several important cell functions. 
Specifically, the RAS/MAPK pathway regulates cell 
proliferation, differentiation, migration and the programmed 
death (apoptosis) [2].  
Among the various Raf kinase isoforms, the B-type RAF 
V600E (BRAFV600E) mutation is the most commonly 
observed inducing excessive proliferation and differentiation of 
tumor cells at the initial tumor stage [3]. 
Mutations in the BRAF serine/threonine kinase represent the 
most common genetic cause in thyroid cancer, occurring in 
approximately 45% of papillary thyroid cancer (PTC) and in a 
lower proportion of poorly differentiated thyroid cancer (PDTC) 
and anaplastic thyroid cancer (ATC) [4].  
Moreover, BRAF gene mutations may be considered as a 
predictive factor for lymph node metastasis, extrathyroid 
extension, advanced disease stages III and IV, and disease 
recurrence [5].  
The importance of the MAPK pathway has been well 
established in the tumorigenesis of PTC. The MAPK pathway is 
driven by activating mutations, including BRAF and RAS 
mutations, RET/PTC, TRK and ALK rearrangements. MAPK-
mediated thyroid tumorigenesis involves a wide range of 
secondary molecular alterations that synergize and amplify the 
oncogenic activity of this pathway, such as genome-wide 
hypermethylation and hypomethylation and altered expression 
of miRNAs. Upregulation of various oncogenic proteins can 
occur and drive cancer cell proliferation, growth, migration and 
survival, as well as tumor angiogenesis, invasion and metastasis 
[6]. 
In a previous work we found that thyroid cancer stem cells 
derived from 8505 cell line are resistant to the BRAF inhibitor 
vemurafenib, despite harboring BRAFV600E mutation. In these 
cancer stem cells the resistance to vemurafenib was mediated by 
a paradoxical over-activation of ERK and AKT pathways. By 
our computational modeling, we found a fundamental role of 
mitogen-activated protein kinase 8 (MAP3K8), a 
serine/threonine kinase expressed in thyroid CSCs, in mediating 
this drug resistance.  Hence, in this paper, we investigate the 
MAP3K8 expression in vivo in a large series of human thyroid 
cancer samples and its relationship to tumor behavior. 
 
II. MATERIALS AND METHODS 
In order to analyse the trend of MAP3K8 expression values 
across all types of thyroid cancers (ATC, PTC, PDTC), the 
following datasets have been selected and downloaded from 
Gene Expression Omnibus data repository 
(https://www.ncbi.nlm.nih.gov/geo/): 
 
- GSE33630 (11 ATC, 49 PTC and 45 normal samples) 
- GSE76039 (17 PDTC and 20 ATC samples) 
- GSE58545 (27 PTC and 18 normal samples) 
- GSE3678 (7 PTC and 7 normal samples). 
 
A. Survival analysis 
Bioconductor survival package [7] has been used to obtain 
Kaplan-Meier survival curves: the Kaplan-Meier estimate is a 
nonparametric maximum likelihood estimate (MLE) of the 
survival function, S(t). This estimate is a step function with 
jumps at observed event times, ti. Kaplan-Meier curves show the 
survival probability over time of specific subjects under specific 
conditions, as shown in Figure 1. Survival analysis was 
performed on data relating to a cohort of patients suffering from 
papillary thyroid cancer (PTC), obtained from the GDC data 
portal (https://portal.gdc.cancer.gov/), within The Cancer 
Genome Atlas (TCGA) project . PTC is the most common form 
of thyroid cancer and since it is less aggressive than ATC it is 
very treatable, especially if diagnosed early and in people under 
50. In order to produce Kaplan-Meier curves, both clinical and 
expression values data were used. 
 
 
Figure 1. Kaplan-Meier curves show the survival probability of groups of 
patients with different BRAF and TPL2 expression levels.   
 
B. Gene expression analysis 
Raw signal intensities for each probe set contained in the 
CEL files were analyzed using different methods implemented 
in Bioconductor statistical programming language R 
(http://bioconductor.org). Bioconductor GEOquery package [8]  
were used for analyses of microarray data. GC-RMA algorithm 
was used for normalization process: GC-RMA algorithm used 
probe sequence information to estimate probe affinity to non-
specific binding. Analysis was performed after normalization of 
the intensities from all of the chips into homogeneous 
distributions. The first step of analysis consisted in filtering out 
uninformative data such as control probesets and other internal 
controls and removing genes with low variance, that could have 
compromised the results of statistical tests for differential 
expression. Once datasets were filtered, data were sent to limma 
package for differential gene expression analysis [9]. 
 
C. Pathway Analysis 
Bioconductor package SPIA [10] has been used to 
implement a Signaling Pathway Impact Analysis (SPIA) on our 
list of differentially expressed genes along with their log fold 
changes and KEGG signaling pathway topologies in order to 
identify most relevant pathways under our conditions of study. 
Among all the 136 pathways we obtained, we selected only 
those where our target gene MAP3K8 was involved in: i) MAPK 
signaling pathway; ii) Toll-like receptor signaling pathway; iii) 
T cell receptor signaling pathway. All the mentioned above 
pathways are respectively depicted in Figure 2, 3 and 4. 
Moreover, single nucleotide polymorphisms  among various 
TLR genes have been identified, and their association with 
susceptibility/resistance to certain infections like pulmonary 
tuberculosis and other inflammatory diseases has been reported 
[11]. 
 
 
Figure 2. MAPK Signaling Pathway, MAP3K8 is in red (alias ID Tpl2/Cot). 
 
 
  
Figure 3. Toll-like receptor signaling pathway: Tpl2 target gene is highlighted 
in red. 
 
 
 
Figure 4. T cell receptor signaling pathway: COT is highlighted in red. 
 
D. Stemness index evaluation 
As cancer progression is accompanied by a gradual loss of 
a differentiated phenotype and the acquisition of stem-cell like 
phenotype, we assessed whether the stemness degree of a 
particular thyroid cancer type could be a predictive parameter 
of tumor outcome. Using a one-class logistic regression 
(OCLR) algorithm trained on stem cell, we derived mRNA 
expression-based stemness index (mRNAsi) on 37 samples of 
our selected dataset GSE76039 [12]. Stemness index values 
range from low (0) to high (1): after calculating mRNAsi for 
each sample of our reference dataset, we ranked our data 
depending on mRNAsi value thus obtaining two groups, one 
showing high index values and the other one showing low index 
values, using a 0.5 value as cut-off. Then, we repeated 
differentially expressed genes (DEG) analysis on each group 
separately looking for any correlation between high or low 
index values and MAP3K8 expression levels. 
 
III. RESULTS 
Differentially expressed genes (DEGs) analysis was 
performed on each dataset individually first, and then extended 
to all datasets simultaneously to compare expression values 
across all samples.  
DEGs analysis provided a list with all genes displaying any 
changes in expression levels between normal and cancer 
samples. This list includes many genes whose involvement in 
many types of tumor formation is widely discussed in literature, 
as shown in Figure 5. 
 
 
 
Figure 5. This graphic shows the correlation between different cancer types and 
some of the genes of our DEGs list. 
 
Survival analysis was conducted in order to find out whether 
any alteration in differentially expressed genes expression 
values correlates with worse survival or earlier tumor 
recurrence. Survival curves, indeed, showed that death 
probability is higher in case of both BRAF mutation and 
MAP3K8 high expression levels, thus confirming MAP3K8 
role as antagonist to BRAF inhibitor drugs. DEGs analysis 
conducted simultaneously on all Thyroid cancer types across all 
samples showed a MAP3K8 over-expression in case of ATCs, 
with almost doubled expression values in ATCs compared to 
normal samples (Table 1). 
 
TABLE I.  DEGS ANALYSIS SHOWS MAP3K8 EXPRESSION VALUES 
ACROSS ALL TYPES OF THYROID CANCER. 
 
TABLE II.  DEGS ANALYSIS SHOWS HRAS AND NRAS EXPRESSION 
VALUES ACROSS ALL TYPES OF THYROID CANCER. 
 
 
Even if this over-expression of H- and N-RAS is not as 
significant as the one of MAP3K8, it could be interesting to 
analyse any correlation between RAS and MAP3K8 up-
regolation, since they have been associated with higher 
malignancy and shorter overall survival rate in PDTC [13], and 
their mutations are among the most common genetic alterations 
leading to tumors formation, along with BRAF mutation.  
Stemness index evaluation showed a correlation between 
higher index values and MAP3K8 higher expression levels but 
this aspect needs to be further investigated in future.  
MAP3K8 up-regulation in ATC samples could suggest 
possible correlations with some clinico-pathological parameters 
which are typical features of this tumor type. For example, as 
ATC is a rare and aggressive form of thyroid cancer that affects 
mainly elderlies displaying high prevalence of BRAF-V600E 
mutation, it is clear that a strong correlation between age and 
BRAF mutation exists. The possibility to detect this MAP3K8 
over expression in previous tumor stages or in earlier ages could 
be a very powerful strategy for early diagnosis and prevention. 
Recent studies demonstrated that a sub-type of tumor cells 
showing stem cell like properties may harbor particularly 
aggressive phenotypes such as a strong therapy resistance and a 
high ability to metastasize. Since cancer progression involves 
the acquisition of stem-cell-like features we tried to evaluate the 
stemness degree of this particular thyroid cancer type: a high 
stemness degree corresponding to a massive presence of stem 
cell like features could be a predictive parameter of tumor 
outcome, and could give useful indications about its course 
Pathway analysis conducted on our DEGs list, showed that 
MAP3K8 is involved in MAPK signaling pathway, Toll-like 
receptor signaling pathway and T cell receptor signaling 
pathway.  
Moreover, it is worth to mention how, among these 
pathways, a fundamental role of immune system dynamics is 
interestingly involved. Respectively, the activation of MAPK 
pathway, is crucial for transcriptional and nontranscriptional 
responses of the immune system [14]; toll-like receptor 
signaling pathway leads to activation of the transcription factors 
NF-κB and IRFs, which dictate the outcome of innate immune 
responses [15] and T cell receptor signaling pathway T-cell-
receptor (TCR) signaling in response to antigen recognition has 
a central role in the adaptive immune response [16]. 
This demonstrates that MAP3K8 plays a decisive role in cell 
proliferation and in all the inflammatory events related to the 
tumor formation process and that a link between cancer and 
immune system is present. 
 
IV. CONCLUSIONS 
The involvement of MAP3K8 in the formation and 
progression of thyroid cancer has been discussed in literature, as 
well as its contribution to vemurafenib resistance of mutant 
BRAF V600E thyroid cancer. Here we demonstrated that high 
values of MAP3K8 expression are related to a particularly 
aggressive and lethal tumor type, ATC.  The possibility of 
considering MAP3K8 as a prognostic biomarker would be a 
great chance both to predict response to therapy and the 
progression of cancer itself but needs to be confirmed by future 
in vivo experiments. Moreover, functional variation of TLR4 
genes is involved in chronic obstructive pulmonary disease and 
pulmonary tuberculosis: this makes MAP3K8 a possible target 
 
 
 
 
 
 
 
Gene Symbol Normal ATC PDTC 
MAP3K8 2.745913 4.481513 3.450524 
Gene Symbol Normal ATC PDTC 
HRAS 7,318032 9,757364 8,545390 
NRAS 7,245183 8,390965 6,616174 
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for investigating its potential roles both for diagnostic and 
prognostic biomarker in tuberculosis. 
 
 
ACKNOWLEDGMENT 
Authors of this paper acknowledge support from the STriTuVaD 
project. The STriTuVaD project has been funded by the 
European Commission, under the contract H2020-SC1-2017- 
CNECT-2, No. 777123. The information and views set out in 
this article are those of the authors and do not necessarily reflect 
the official opinion of the European Commission. Neither the 
European Commission institutions and bodies nor any person 
acting on their behalf may be held responsible for the use which 
may be made of the information contained therein.  
 
REFERENCES 
 
[1] J. R. Burgess and P. Tucker, “Incidence trends for papillary thyroid 
carcinoma and their correlation with thyroid surgery and thyroid 
fine-needle aspirate cytology,” Thyroid, 2006. 
[2] S. Chiosea et al., “A novel complex BRAF mutation detected in a 
solid variant of papillary thyroid carcinoma,” Endocr. Pathol., 2009. 
[3] M. Xing, B. R. Haugen, and M. Schlumberger, “Progress in 
molecular-based management of differentiated thyroid cancer,” The 
Lancet. 2013. 
[4] F. Gianì, G. Russo, M. Pennisi, L. Sciacca, F. Frasca, and F. 
Pappalardo, “Computational modeling reveals MAP3K8 as 
mediator of resistance to vemurafenib in thyroid cancer stem cells,” 
Bioinformatics, vol. 35, no. 13, pp. 2267–2275, Jul. 2019. 
[5] C. Yan, M. Huang, X. Li, T. Wang, and R. Ling, “Relationship 
between BRAF V600E and clinical features in papillary thyroid 
carcinoma,” Endocr. Connect., 2019. 
[6] E. Younis, “Oncogenesis of thyroid cancer,” Asian Pacific Journal 
of Cancer Prevention. 2017. 
[7] H. Lin and D. Zelterman, “Modeling Survival Data: Extending the 
Cox Model,” Technometrics, 2002. 
[8] D. Sean and P. S. Meltzer, “GEOquery: A bridge between the Gene 
Expression Omnibus (GEO) and BioConductor,” Bioinformatics, 
2007. 
[9] M. E. Ritchie et al., “Limma powers differential expression analyses 
for RNA-sequencing and microarray studies,” Nucleic Acids Res., 
2015. 
[10] A. L. Tarca et al., “A novel signaling pathway impact analysis,” 
Bioinformatics, 2009. 
[11] Z. Li et al., “Functional variations of the TLR4 gene in association 
with chronic obstructive pulmonary disease and pulmonary 
tuberculosis.,” BMC Pulm. Med., vol. 19, no. 1, p. 184, Oct. 2019. 
[12] T. M. Malta et al., “Machine Learning Identifies Stemness Features 
Associated with Oncogenic Dedifferentiation,” Cell, 2018. 
[13] Y. E. Nikiforov and M. N. Nikiforova, “Molecular genetics and 
diagnosis of thyroid cancer,” Nat. Rev. Endocrinol., vol. 7, no. 10, 
pp. 569–580, Aug. 2011. 
[14] Y. Liu, E. G. Shepherd, and L. D. Nelin, “MAPK phosphatases - 
Regulating the immune response,” Nature Reviews Immunology. 
2007. 
[15] T. Kawasaki and T. Kawai, “Toll-Like Receptor Signaling 
Pathways,” Front. Immunol., vol. 5, no. 2, pp. 124–128, Sep. 2014. 
[16] M. Huse, “The T-cell-receptor signaling network,” J. Cell Sci., vol. 
122, no. 9, pp. 1269–1273, May 2009. 
 
